SeaSpine announced preliminary 2Q17 revenue in the range of US $34.0MM to $34.2MM, +3% vs. 2Q16. (U.S. $30.4MM, +1%, ex-U.S. $3.8MM, +0.2%)
Based on SeaSpine’s estimates, quarterly and 1H17 revenues by segment are expected to approximate the following:
2Q17Â
2Q16Â
$ ChangeÂ
% ChangeÂ
 Spine
$16.6Â
$16.4Â
$0.2Â
1.2%Â
 Orthobiologics
$17.6Â
$16.8Â
$0.8Â
4.7%Â
TotalÂ
$34.2Â
$33.2Â
$1.0Â
3.0%Â
1H17Â
1H16Â
$ ChangeÂ
% ChangeÂ
 Spine
$31.4Â
$31.1Â
$0.2Â
0.7%Â
 Orthobiologics
$34.7Â
$33.5Â
$1.3Â
3.8%Â
TotalÂ
$66.1Â
$64.6Â
$1.5Â
2.3%Â
The company’s recent completion of full commercial launch of its Mariner Posterior Fixation system reflects its continuing focus on expanding its product portfolio.
SeaSpine announced preliminary 2Q17 revenue in the range of US $34.0MM to $34.2MM, +3% vs. 2Q16. (U.S. $30.4MM, +1%, ex-U.S. $3.8MM, +0.2%)
Based on SeaSpine's estimates, quarterly and 1H17 revenues by segment are expected to approximate the following:
Q17Â Q16Â $...
SeaSpine announced preliminary 2Q17 revenue in the range of US $34.0MM to $34.2MM, +3% vs. 2Q16. (U.S. $30.4MM, +1%, ex-U.S. $3.8MM, +0.2%)
Based on SeaSpine’s estimates, quarterly and 1H17 revenues by segment are expected to approximate the following:
2Q17Â
2Q16Â
$ ChangeÂ
% ChangeÂ
 Spine
$16.6Â
$16.4Â
$0.2Â
1.2%Â
 Orthobiologics
$17.6Â
$16.8Â
$0.8Â
4.7%Â
TotalÂ
$34.2Â
$33.2Â
$1.0Â
3.0%Â
1H17Â
1H16Â
$ ChangeÂ
% ChangeÂ
 Spine
$31.4Â
$31.1Â
$0.2Â
0.7%Â
 Orthobiologics
$34.7Â
$33.5Â
$1.3Â
3.8%Â
TotalÂ
$66.1Â
$64.6Â
$1.5Â
2.3%Â
The company’s recent completion of full commercial launch of its Mariner Posterior Fixation system reflects its continuing focus on expanding its product portfolio.
Copy to clipboard 
